Free Trial
TSE:FRX

Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

Fennec Pharmaceuticals logo
C$9.50 +0.63 (+7.10%)
As of 02/21/2025 03:47 PM Eastern

About Fennec Pharmaceuticals Stock (TSE:FRX)

Key Stats

Today's Range
C$9.50
C$9.50
50-Day Range
C$7.90
C$9.80
52-Week Range
C$5.65
C$15.20
Volume
100 shs
Average Volume
1,771 shs
Market Capitalization
C$183.20 million
P/E Ratio
N/A
Dividend Yield
2.02%
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Receive FRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FRX Stock News Headlines

Fennec Pharmaceuticals (FENC) Gets a Buy from Craig-Hallum
Your trading day could end at 11 AM
What do you usually do between 9:35 AM and 11:00 AM? Catch up on emails? Attend a meeting? Maybe grab a coffee? For me, it's become the most important part of my trading day. 85 minutes. That's usually all it takes. Set up at 9:35 AM… Check back at 11:00 AM. And when things work out, there's an extra $100 to $150 in my account… on a $1000 starting stake. Sounds too simple, doesn't it?
Fennec announces three executive appointments
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc (FRX)
See More Headlines

FRX Stock Analysis - Frequently Asked Questions

Fennec Pharmaceuticals' stock was trading at C$8.87 at the beginning of 2025. Since then, FRX stock has increased by 7.1% and is now trading at C$9.50.
View the best growth stocks for 2025 here
.

Fennec Pharmaceuticals Inc. (TSE:FRX) issued its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative net margin of 2.30% and a positive trailing twelve-month return on equity of 29.94%.

Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Fennec Pharmaceuticals (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS).

Company Calendar

Last Earnings
11/07/2024
Today
2/22/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
C$-800,437.92
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$34.86 million
Cash Flow
C$0.81 per share
Book Value
C($0.19) per share

Miscellaneous

Free Float
N/A
Market Cap
C$183.20 million
Optionable
Not Optionable
Beta
0.25
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (TSE:FRX) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners